| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 101 | 2025 | 2456 | 10.490 |
Why?
|
| Antineoplastic Agents, Hormonal | 24 | 2021 | 194 | 5.270 |
Why?
|
| Receptors, Estrogen | 36 | 2025 | 457 | 4.790 |
Why?
|
| Aromatase Inhibitors | 18 | 2022 | 75 | 4.070 |
Why?
|
| Drug Resistance, Neoplasm | 19 | 2024 | 883 | 2.870 |
Why?
|
| Estrogen Receptor alpha | 11 | 2023 | 161 | 2.680 |
Why?
|
| Neoadjuvant Therapy | 20 | 2024 | 463 | 2.550 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 23 | 2024 | 1958 | 2.360 |
Why?
|
| Nitriles | 15 | 2024 | 205 | 2.360 |
Why?
|
| Triazoles | 15 | 2024 | 184 | 2.320 |
Why?
|
| Biomarkers, Tumor | 25 | 2024 | 1322 | 2.270 |
Why?
|
| Triple Negative Breast Neoplasms | 9 | 2024 | 216 | 2.180 |
Why?
|
| Cyclin-Dependent Kinase 4 | 8 | 2025 | 53 | 2.100 |
Why?
|
| Cyclin-Dependent Kinase 6 | 7 | 2025 | 49 | 2.050 |
Why?
|
| Proteogenomics | 7 | 2022 | 12 | 2.030 |
Why?
|
| Mutation | 27 | 2024 | 4099 | 1.900 |
Why?
|
| Antineoplastic Agents | 17 | 2024 | 2197 | 1.620 |
Why?
|
| Ki-67 Antigen | 9 | 2024 | 117 | 1.410 |
Why?
|
| Neoplasms, Hormone-Dependent | 5 | 2016 | 41 | 1.370 |
Why?
|
| Gene Expression Profiling | 15 | 2021 | 1786 | 1.180 |
Why?
|
| Proteomics | 19 | 2022 | 1195 | 1.180 |
Why?
|
| Protein Kinase Inhibitors | 10 | 2025 | 970 | 1.140 |
Why?
|
| Quinolines | 5 | 2022 | 193 | 1.070 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 6 | 2018 | 109 | 0.990 |
Why?
|
| Opioid-Related Disorders | 6 | 2025 | 601 | 0.980 |
Why?
|
| Female | 114 | 2025 | 78376 | 0.970 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2015 | 88 | 0.950 |
Why?
|
| Xenograft Model Antitumor Assays | 17 | 2025 | 930 | 0.910 |
Why?
|
| Neoplasm Recurrence, Local | 13 | 2022 | 1141 | 0.850 |
Why?
|
| Humans | 135 | 2025 | 144957 | 0.850 |
Why?
|
| Chemotherapy, Adjuvant | 13 | 2020 | 421 | 0.840 |
Why?
|
| Trastuzumab | 5 | 2020 | 118 | 0.840 |
Why?
|
| Postmenopause | 8 | 2024 | 391 | 0.830 |
Why?
|
| Estradiol | 7 | 2016 | 533 | 0.830 |
Why?
|
| Prognosis | 21 | 2022 | 4293 | 0.820 |
Why?
|
| Piperazines | 6 | 2025 | 381 | 0.810 |
Why?
|
| Neoplasm Staging | 17 | 2019 | 1465 | 0.740 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2024 | 128 | 0.720 |
Why?
|
| Pyridines | 6 | 2025 | 605 | 0.720 |
Why?
|
| Circulating Tumor DNA | 2 | 2022 | 44 | 0.680 |
Why?
|
| Tamoxifen | 8 | 2019 | 217 | 0.650 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2017 | 437 | 0.620 |
Why?
|
| Disease-Free Survival | 11 | 2019 | 769 | 0.610 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 211 | 0.610 |
Why?
|
| Estrogens | 3 | 2011 | 380 | 0.590 |
Why?
|
| Heterografts | 7 | 2021 | 144 | 0.580 |
Why?
|
| Cell Line, Tumor | 16 | 2025 | 3550 | 0.580 |
Why?
|
| MutL Proteins | 2 | 2021 | 3 | 0.580 |
Why?
|
| Gene Expression Regulation, Neoplastic | 15 | 2021 | 1462 | 0.570 |
Why?
|
| Gene Fusion | 1 | 2018 | 29 | 0.560 |
Why?
|
| Receptors, Progesterone | 9 | 2018 | 356 | 0.540 |
Why?
|
| HIV Infections | 2 | 2024 | 3154 | 0.540 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2018 | 381 | 0.540 |
Why?
|
| Middle Aged | 46 | 2025 | 35928 | 0.530 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2017 | 27 | 0.530 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2018 | 966 | 0.520 |
Why?
|
| Molecular Sequence Annotation | 3 | 2016 | 105 | 0.520 |
Why?
|
| Transcriptome | 9 | 2021 | 1046 | 0.510 |
Why?
|
| Genomics | 9 | 2022 | 836 | 0.510 |
Why?
|
| Cell Proliferation | 9 | 2025 | 2499 | 0.500 |
Why?
|
| Aged | 40 | 2024 | 25947 | 0.500 |
Why?
|
| Gene Amplification | 6 | 2017 | 121 | 0.490 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2017 | 58 | 0.490 |
Why?
|
| Aromatase | 1 | 2016 | 32 | 0.490 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2015 | 70 | 0.480 |
Why?
|
| Proteome | 7 | 2020 | 518 | 0.480 |
Why?
|
| Neoplasms | 9 | 2022 | 2884 | 0.470 |
Why?
|
| Neoplasm Metastasis | 6 | 2018 | 695 | 0.460 |
Why?
|
| Genome, Human | 3 | 2016 | 422 | 0.460 |
Why?
|
| Treatment Outcome | 17 | 2021 | 11695 | 0.440 |
Why?
|
| Mice | 27 | 2025 | 18365 | 0.430 |
Why?
|
| Selective Estrogen Receptor Modulators | 3 | 2016 | 36 | 0.430 |
Why?
|
| Animals | 34 | 2025 | 38109 | 0.430 |
Why?
|
| Carcinoma, Lobular | 1 | 2014 | 56 | 0.410 |
Why?
|
| Signal Transduction | 17 | 2021 | 5233 | 0.410 |
Why?
|
| Apoptosis | 6 | 2024 | 2430 | 0.410 |
Why?
|
| Survival Analysis | 8 | 2019 | 1385 | 0.400 |
Why?
|
| Pharmaceutical Services, Online | 1 | 2012 | 1 | 0.390 |
Why?
|
| Adult | 37 | 2025 | 40506 | 0.380 |
Why?
|
| Proportional Hazards Models | 6 | 2019 | 1325 | 0.380 |
Why?
|
| Neurofibromin 1 | 2 | 2025 | 26 | 0.370 |
Why?
|
| Carcinoma | 2 | 2020 | 228 | 0.360 |
Why?
|
| MCF-7 Cells | 6 | 2021 | 135 | 0.360 |
Why?
|
| Ergocalciferols | 1 | 2011 | 14 | 0.350 |
Why?
|
| E2F Transcription Factors | 1 | 2011 | 62 | 0.350 |
Why?
|
| Prescription Drugs | 1 | 2012 | 111 | 0.340 |
Why?
|
| Bone Density Conservation Agents | 1 | 2011 | 81 | 0.320 |
Why?
|
| Endocrine System | 1 | 2010 | 22 | 0.320 |
Why?
|
| RNA, Messenger | 3 | 2021 | 2832 | 0.320 |
Why?
|
| Combined Modality Therapy | 5 | 2017 | 1268 | 0.310 |
Why?
|
| Musculoskeletal Diseases | 1 | 2011 | 90 | 0.310 |
Why?
|
| Predictive Value of Tests | 5 | 2017 | 2118 | 0.310 |
Why?
|
| Mice, Nude | 4 | 2021 | 688 | 0.300 |
Why?
|
| Androstadienes | 4 | 2017 | 76 | 0.300 |
Why?
|
| Colonic Neoplasms | 3 | 2019 | 260 | 0.300 |
Why?
|
| Mastectomy | 4 | 2015 | 162 | 0.290 |
Why?
|
| Precision Medicine | 1 | 2013 | 458 | 0.290 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2015 | 2365 | 0.280 |
Why?
|
| Antibodies, Monoclonal | 3 | 2013 | 1524 | 0.280 |
Why?
|
| Sequence Analysis, DNA | 3 | 2017 | 824 | 0.280 |
Why?
|
| Protein Kinases | 4 | 2020 | 315 | 0.270 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 3 | 2017 | 44 | 0.270 |
Why?
|
| Survival Rate | 5 | 2021 | 2092 | 0.270 |
Why?
|
| Internet | 1 | 2012 | 700 | 0.270 |
Why?
|
| Oxycodone | 2 | 2025 | 53 | 0.260 |
Why?
|
| Molecular Targeted Therapy | 3 | 2020 | 434 | 0.260 |
Why?
|
| Disease Models, Animal | 8 | 2023 | 4569 | 0.250 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2007 | 63 | 0.250 |
Why?
|
| Antigens, Neoplasm | 3 | 2020 | 272 | 0.240 |
Why?
|
| Aged, 80 and over | 14 | 2021 | 8279 | 0.240 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 1322 | 0.240 |
Why?
|
| Analgesics, Opioid | 4 | 2025 | 1143 | 0.240 |
Why?
|
| Morpholines | 2 | 2018 | 129 | 0.240 |
Why?
|
| Aminopyridines | 2 | 2018 | 127 | 0.240 |
Why?
|
| Paclitaxel | 3 | 2016 | 256 | 0.230 |
Why?
|
| Carboplatin | 2 | 2022 | 160 | 0.220 |
Why?
|
| ROC Curve | 2 | 2017 | 615 | 0.220 |
Why?
|
| Delayed-Action Preparations | 3 | 2025 | 183 | 0.210 |
Why?
|
| Prescription Drug Misuse | 1 | 2025 | 51 | 0.210 |
Why?
|
| Homologous Recombination | 1 | 2024 | 36 | 0.210 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2025 | 1721 | 0.210 |
Why?
|
| Phosphorylation | 8 | 2021 | 1733 | 0.210 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2004 | 56 | 0.210 |
Why?
|
| Neoplasm Transplantation | 4 | 2017 | 252 | 0.210 |
Why?
|
| Needle-Exchange Programs | 1 | 2024 | 15 | 0.200 |
Why?
|
| Healthcare Disparities | 2 | 2025 | 728 | 0.200 |
Why?
|
| Radiation Tolerance | 1 | 2024 | 103 | 0.200 |
Why?
|
| Naloxone | 1 | 2025 | 132 | 0.200 |
Why?
|
| Tramadol | 1 | 2023 | 17 | 0.200 |
Why?
|
| Clinical Decision-Making | 2 | 2017 | 359 | 0.200 |
Why?
|
| DNA Mutational Analysis | 2 | 2016 | 409 | 0.200 |
Why?
|
| Risk Assessment | 7 | 2016 | 3676 | 0.200 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2020 | 451 | 0.200 |
Why?
|
| Abscess | 1 | 2024 | 75 | 0.200 |
Why?
|
| Abuse-Deterrent Formulations | 1 | 2023 | 3 | 0.200 |
Why?
|
| Harm Reduction | 1 | 2024 | 51 | 0.200 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2023 | 27 | 0.200 |
Why?
|
| Drug Compounding | 1 | 2024 | 107 | 0.190 |
Why?
|
| Clinical Trials as Topic | 4 | 2012 | 1054 | 0.190 |
Why?
|
| Ovarian Neoplasms | 3 | 2014 | 586 | 0.190 |
Why?
|
| Risk Factors | 8 | 2023 | 10792 | 0.190 |
Why?
|
| Immunohistochemistry | 5 | 2021 | 1718 | 0.190 |
Why?
|
| Peptides | 4 | 2016 | 998 | 0.190 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2022 | 13 | 0.190 |
Why?
|
| Mass Spectrometry | 5 | 2018 | 750 | 0.190 |
Why?
|
| Chemoradiotherapy | 1 | 2024 | 239 | 0.190 |
Why?
|
| Narcotic Antagonists | 1 | 2025 | 206 | 0.190 |
Why?
|
| Incidence | 5 | 2023 | 2883 | 0.190 |
Why?
|
| Health Equity | 1 | 2025 | 129 | 0.180 |
Why?
|
| Computational Biology | 4 | 2015 | 681 | 0.180 |
Why?
|
| Purines | 1 | 2023 | 187 | 0.180 |
Why?
|
| Transfection | 2 | 2018 | 940 | 0.180 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2009 | 323 | 0.180 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2004 | 321 | 0.180 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2020 | 220 | 0.180 |
Why?
|
| Alleles | 2 | 2016 | 881 | 0.180 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 826 | 0.180 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2015 | 165 | 0.180 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2024 | 433 | 0.170 |
Why?
|
| Transplantation, Heterologous | 4 | 2015 | 194 | 0.170 |
Why?
|
| DNA Mismatch Repair | 1 | 2021 | 52 | 0.170 |
Why?
|
| Transcription Factor AP-1 | 1 | 2020 | 79 | 0.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2025 | 1416 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2015 | 988 | 0.160 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2020 | 15 | 0.160 |
Why?
|
| Basal Ganglia Diseases | 1 | 2020 | 9 | 0.160 |
Why?
|
| Maximum Tolerated Dose | 3 | 2016 | 212 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 919 | 0.150 |
Why?
|
| Calcium-Binding Proteins | 2 | 2018 | 220 | 0.150 |
Why?
|
| Buprenorphine | 1 | 2023 | 191 | 0.150 |
Why?
|
| Mastectomy, Segmental | 3 | 2015 | 108 | 0.150 |
Why?
|
| Carrier Proteins | 1 | 2023 | 737 | 0.150 |
Why?
|
| Cohort Studies | 3 | 2020 | 5965 | 0.140 |
Why?
|
| Discoidin Domain Receptor 1 | 1 | 2018 | 3 | 0.140 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2020 | 230 | 0.140 |
Why?
|
| Class Ia Phosphatidylinositol 3-Kinase | 1 | 2018 | 8 | 0.140 |
Why?
|
| Carcinogenesis | 1 | 2020 | 229 | 0.140 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2018 | 19 | 0.140 |
Why?
|
| Influenza Vaccines | 1 | 2023 | 529 | 0.140 |
Why?
|
| tau Proteins | 1 | 2020 | 115 | 0.140 |
Why?
|
| Kidney Transplantation | 1 | 2025 | 704 | 0.140 |
Why?
|
| DNA Glycosylases | 1 | 2018 | 10 | 0.140 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2025 | 653 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 199 | 0.140 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2018 | 8 | 0.140 |
Why?
|
| Endonucleases | 1 | 2018 | 34 | 0.140 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2018 | 23 | 0.140 |
Why?
|
| NIMA-Related Kinases | 1 | 2018 | 9 | 0.140 |
Why?
|
| Imidazoles | 2 | 2010 | 254 | 0.140 |
Why?
|
| Thymidine Kinase | 1 | 2017 | 16 | 0.140 |
Why?
|
| Transcriptional Activation | 2 | 2018 | 383 | 0.140 |
Why?
|
| Time Factors | 5 | 2016 | 7183 | 0.130 |
Why?
|
| Centrifugation, Density Gradient | 1 | 2017 | 40 | 0.130 |
Why?
|
| Drug Synergism | 2 | 2016 | 357 | 0.130 |
Why?
|
| Genomic Instability | 2 | 2020 | 66 | 0.130 |
Why?
|
| Neurodegenerative Diseases | 1 | 2020 | 151 | 0.130 |
Why?
|
| Phosphoproteins | 3 | 2016 | 346 | 0.130 |
Why?
|
| Down-Regulation | 1 | 2020 | 627 | 0.130 |
Why?
|
| Endometrial Neoplasms | 1 | 2020 | 208 | 0.130 |
Why?
|
| Adenocarcinoma | 2 | 2015 | 931 | 0.130 |
Why?
|
| Translocation, Genetic | 2 | 2018 | 118 | 0.130 |
Why?
|
| Reproducibility of Results | 3 | 2017 | 3415 | 0.130 |
Why?
|
| Neoplasm Proteins | 3 | 2017 | 444 | 0.130 |
Why?
|
| Mitotic Index | 1 | 2017 | 25 | 0.130 |
Why?
|
| RNA, Neoplasm | 2 | 2014 | 86 | 0.120 |
Why?
|
| Spiro Compounds | 1 | 2016 | 17 | 0.120 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 735 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2015 | 2147 | 0.120 |
Why?
|
| Enzyme Activation | 4 | 2017 | 768 | 0.120 |
Why?
|
| Estrogen Receptor Antagonists | 1 | 2016 | 4 | 0.120 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2016 | 49 | 0.120 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 345 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 1099 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 66 | 0.120 |
Why?
|
| Proteolysis | 1 | 2017 | 173 | 0.120 |
Why?
|
| Tandem Mass Spectrometry | 5 | 2017 | 577 | 0.120 |
Why?
|
| Clone Cells | 1 | 2016 | 266 | 0.120 |
Why?
|
| SEER Program | 2 | 2014 | 224 | 0.120 |
Why?
|
| Point Mutation | 2 | 2014 | 243 | 0.120 |
Why?
|
| RNA Interference | 3 | 2018 | 476 | 0.120 |
Why?
|
| United States | 7 | 2025 | 15988 | 0.120 |
Why?
|
| Genes, Neoplasm | 1 | 2015 | 25 | 0.120 |
Why?
|
| Retreatment | 1 | 2015 | 77 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2016 | 531 | 0.110 |
Why?
|
| Capecitabine | 1 | 2015 | 57 | 0.110 |
Why?
|
| Risk | 2 | 2015 | 911 | 0.110 |
Why?
|
| RNA, Small Interfering | 3 | 2018 | 635 | 0.110 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2015 | 117 | 0.110 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2016 | 96 | 0.110 |
Why?
|
| Salvage Therapy | 1 | 2016 | 162 | 0.110 |
Why?
|
| Epitopes | 1 | 2017 | 485 | 0.110 |
Why?
|
| Genotype | 3 | 2015 | 1835 | 0.110 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 377 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2018 | 428 | 0.110 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 5417 | 0.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2019 | 917 | 0.110 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2018 | 82 | 0.110 |
Why?
|
| Biomarkers | 3 | 2017 | 4275 | 0.110 |
Why?
|
| Receptor, ErbB-3 | 1 | 2014 | 48 | 0.110 |
Why?
|
| Neoplasm Grading | 4 | 2017 | 309 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 983 | 0.110 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 1540 | 0.110 |
Why?
|
| Neuregulin-1 | 1 | 2014 | 49 | 0.100 |
Why?
|
| Cell Cycle | 1 | 2017 | 597 | 0.100 |
Why?
|
| Cancer Survivors | 1 | 2019 | 327 | 0.100 |
Why?
|
| Specimen Handling | 1 | 2016 | 186 | 0.100 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 629 | 0.100 |
Why?
|
| Clonal Evolution | 1 | 2014 | 47 | 0.100 |
Why?
|
| National Human Genome Research Institute (U.S.) | 1 | 2013 | 1 | 0.100 |
Why?
|
| Pilot Projects | 1 | 2020 | 1890 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 4 | 2018 | 509 | 0.100 |
Why?
|
| Asphyxia Neonatorum | 1 | 2013 | 18 | 0.100 |
Why?
|
| Cold Ischemia | 1 | 2014 | 40 | 0.100 |
Why?
|
| Cell Cycle Checkpoints | 3 | 2020 | 99 | 0.100 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2013 | 52 | 0.100 |
Why?
|
| Genes, erbB-2 | 1 | 2013 | 33 | 0.100 |
Why?
|
| Neoplasms, Basal Cell | 1 | 2013 | 4 | 0.100 |
Why?
|
| Osteoporotic Fractures | 1 | 2014 | 61 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 1 | 2014 | 178 | 0.100 |
Why?
|
| Alternative Splicing | 1 | 2015 | 249 | 0.100 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 442 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 592 | 0.100 |
Why?
|
| Central Nervous System Diseases | 1 | 2013 | 74 | 0.100 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 256 | 0.090 |
Why?
|
| Rectal Neoplasms | 1 | 2014 | 158 | 0.090 |
Why?
|
| Protein Biosynthesis | 1 | 2015 | 458 | 0.090 |
Why?
|
| Sirolimus | 3 | 2013 | 281 | 0.090 |
Why?
|
| NIH 3T3 Cells | 1 | 2012 | 148 | 0.090 |
Why?
|
| Young Adult | 9 | 2025 | 14126 | 0.090 |
Why?
|
| Amino Acid Sequence | 2 | 2015 | 2157 | 0.090 |
Why?
|
| Indoles | 1 | 2016 | 501 | 0.090 |
Why?
|
| Stroke Volume | 1 | 2016 | 651 | 0.090 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2016 | 392 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2015 | 502 | 0.090 |
Why?
|
| Ventricular Function, Left | 1 | 2016 | 541 | 0.090 |
Why?
|
| Pain | 2 | 2023 | 782 | 0.090 |
Why?
|
| Lymphatic Metastasis | 2 | 2015 | 334 | 0.090 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2012 | 396 | 0.090 |
Why?
|
| Disease Progression | 2 | 2020 | 2852 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2016 | 758 | 0.090 |
Why?
|
| Hyperglycemia | 1 | 2016 | 375 | 0.090 |
Why?
|
| Osteoporosis | 1 | 2014 | 236 | 0.090 |
Why?
|
| Gene Expression | 2 | 2015 | 1490 | 0.090 |
Why?
|
| Bone Density | 2 | 2014 | 482 | 0.080 |
Why?
|
| Quinazolines | 1 | 2012 | 266 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2013 | 319 | 0.080 |
Why?
|
| Poison Control Centers | 2 | 2025 | 84 | 0.080 |
Why?
|
| Parathyroid Hormone | 1 | 2011 | 112 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2018 | 1500 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2018 | 3608 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2015 | 984 | 0.080 |
Why?
|
| Global Health | 1 | 2013 | 401 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 862 | 0.080 |
Why?
|
| Chromatography, Liquid | 3 | 2017 | 454 | 0.080 |
Why?
|
| Mice, Inbred NOD | 3 | 2017 | 610 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2021 | 2032 | 0.080 |
Why?
|
| Retinoblastoma Protein | 2 | 2020 | 61 | 0.080 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2010 | 61 | 0.080 |
Why?
|
| Genes, BRCA1 | 1 | 2010 | 45 | 0.080 |
Why?
|
| Diphosphonates | 1 | 2010 | 68 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 642 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 562 | 0.070 |
Why?
|
| Cell Growth Processes | 1 | 2009 | 50 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 783 | 0.070 |
Why?
|
| Radiopharmaceuticals | 1 | 2009 | 207 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2009 | 162 | 0.070 |
Why?
|
| Missouri | 2 | 2023 | 66 | 0.070 |
Why?
|
| Age Factors | 4 | 2019 | 3335 | 0.070 |
Why?
|
| Male | 11 | 2025 | 72406 | 0.070 |
Why?
|
| Mice, SCID | 2 | 2021 | 369 | 0.070 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 2931 | 0.070 |
Why?
|
| Double-Blind Method | 2 | 2016 | 2029 | 0.070 |
Why?
|
| Neoplasms, Second Primary | 1 | 2009 | 100 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 5872 | 0.070 |
Why?
|
| DNA Copy Number Variations | 2 | 2022 | 183 | 0.070 |
Why?
|
| Vitamin D | 1 | 2011 | 400 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 343 | 0.070 |
Why?
|
| Health Planning Guidelines | 1 | 2007 | 24 | 0.070 |
Why?
|
| Models, Molecular | 1 | 2012 | 1619 | 0.070 |
Why?
|
| Prospective Studies | 5 | 2019 | 7997 | 0.070 |
Why?
|
| Trinidad and Tobago | 2 | 2018 | 5 | 0.060 |
Why?
|
| Cyclophosphamide | 2 | 2020 | 266 | 0.060 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2009 | 212 | 0.060 |
Why?
|
| Perception | 1 | 2010 | 377 | 0.060 |
Why?
|
| DNA Repair | 2 | 2020 | 256 | 0.060 |
Why?
|
| Cell Line | 1 | 2012 | 2882 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2021 | 336 | 0.060 |
Why?
|
| Microsatellite Repeats | 2 | 2020 | 157 | 0.060 |
Why?
|
| Genes, erbB-1 | 1 | 2006 | 21 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2015 | 2438 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2014 | 683 | 0.060 |
Why?
|
| Genome | 2 | 2021 | 306 | 0.060 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 1389 | 0.060 |
Why?
|
| Immunotherapy | 2 | 2021 | 657 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2008 | 1311 | 0.060 |
Why?
|
| Forecasting | 1 | 2007 | 391 | 0.060 |
Why?
|
| Quality of Life | 2 | 2009 | 3192 | 0.060 |
Why?
|
| Cyclin D1 | 1 | 2025 | 62 | 0.060 |
Why?
|
| ErbB Receptors | 2 | 2021 | 629 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2013 | 1742 | 0.060 |
Why?
|
| Calcium | 1 | 2011 | 1184 | 0.060 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2020 | 477 | 0.060 |
Why?
|
| Phenotype | 1 | 2013 | 3164 | 0.060 |
Why?
|
| Algorithms | 3 | 2019 | 1839 | 0.050 |
Why?
|
| Endpoint Determination | 1 | 2005 | 83 | 0.050 |
Why?
|
| Rad51 Recombinase | 1 | 2024 | 15 | 0.050 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2025 | 133 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2005 | 139 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2004 | 83 | 0.050 |
Why?
|
| BRCA2 Protein | 1 | 2024 | 67 | 0.050 |
Why?
|
| BRCA1 Protein | 1 | 2024 | 81 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2007 | 476 | 0.050 |
Why?
|
| Comparative Effectiveness Research | 1 | 2025 | 170 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2006 | 636 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2017 | 550 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 783 | 0.050 |
Why?
|
| Oxymorphone | 1 | 2023 | 5 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2006 | 427 | 0.050 |
Why?
|
| Phenols | 1 | 2023 | 114 | 0.050 |
Why?
|
| Proteins | 2 | 2021 | 1022 | 0.050 |
Why?
|
| Cisplatin | 1 | 2024 | 334 | 0.050 |
Why?
|
| Recurrence | 2 | 2015 | 1135 | 0.040 |
Why?
|
| Staurosporine | 2 | 2012 | 22 | 0.040 |
Why?
|
| Brazil | 1 | 2022 | 180 | 0.040 |
Why?
|
| Nursing Homes | 1 | 2023 | 172 | 0.040 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2021 | 10 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2016 | 1003 | 0.040 |
Why?
|
| Radiotherapy | 2 | 2015 | 206 | 0.040 |
Why?
|
| APOBEC Deaminases | 1 | 2020 | 6 | 0.040 |
Why?
|
| Genes, cdc | 1 | 2020 | 11 | 0.040 |
Why?
|
| Camptothecin | 2 | 2012 | 140 | 0.040 |
Why?
|
| Drug Overdose | 1 | 2025 | 370 | 0.040 |
Why?
|
| Bridged-Ring Compounds | 1 | 2020 | 31 | 0.040 |
Why?
|
| Anthracyclines | 1 | 2020 | 47 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2025 | 544 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 245 | 0.040 |
Why?
|
| Feedback, Physiological | 1 | 2020 | 83 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2020 | 192 | 0.040 |
Why?
|
| Taxoids | 1 | 2020 | 116 | 0.040 |
Why?
|
| Estrogen Antagonists | 1 | 2019 | 48 | 0.040 |
Why?
|
| Acetylation | 1 | 2020 | 256 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2019 | 54 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2020 | 235 | 0.040 |
Why?
|
| Premenopause | 1 | 2019 | 123 | 0.040 |
Why?
|
| Methotrexate | 1 | 2020 | 240 | 0.040 |
Why?
|
| Cell Hypoxia | 1 | 2019 | 247 | 0.040 |
Why?
|
| Goosecoid Protein | 1 | 2018 | 2 | 0.030 |
Why?
|
| Keratin-19 | 1 | 2018 | 4 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2018 | 18 | 0.030 |
Why?
|
| Biological Mimicry | 1 | 2017 | 2 | 0.030 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2018 | 46 | 0.030 |
Why?
|
| DNA Damage | 1 | 2020 | 430 | 0.030 |
Why?
|
| Medicare | 1 | 2023 | 887 | 0.030 |
Why?
|
| Cell Survival | 1 | 2021 | 1098 | 0.030 |
Why?
|
| Epitope Mapping | 1 | 2017 | 61 | 0.030 |
Why?
|
| RNA, Double-Stranded | 1 | 2017 | 56 | 0.030 |
Why?
|
| Glycolysis | 1 | 2019 | 340 | 0.030 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2017 | 39 | 0.030 |
Why?
|
| Web Browser | 1 | 2016 | 14 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2017 | 125 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2018 | 202 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2025 | 1177 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2016 | 51 | 0.030 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinase 2 | 1 | 2016 | 5 | 0.030 |
Why?
|
| p21-Activated Kinases | 1 | 2016 | 14 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2017 | 177 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2016 | 28 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2018 | 320 | 0.030 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2016 | 20 | 0.030 |
Why?
|
| Cerebral Cortex | 1 | 2020 | 465 | 0.030 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2016 | 32 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2017 | 205 | 0.030 |
Why?
|
| Exome | 1 | 2017 | 227 | 0.030 |
Why?
|
| Interferons | 1 | 2017 | 188 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2016 | 124 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2016 | 93 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2016 | 510 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2017 | 340 | 0.030 |
Why?
|
| Quality Control | 1 | 2015 | 163 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2015 | 327 | 0.030 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2016 | 123 | 0.030 |
Why?
|
| Viruses | 1 | 2017 | 165 | 0.030 |
Why?
|
| Molecular Typing | 1 | 2014 | 21 | 0.030 |
Why?
|
| Metabolomics | 1 | 2020 | 727 | 0.030 |
Why?
|
| Geography | 1 | 2015 | 203 | 0.030 |
Why?
|
| Observer Variation | 1 | 2015 | 355 | 0.030 |
Why?
|
| Neoplastic Processes | 1 | 2014 | 5 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1695 | 0.030 |
Why?
|
| Antibodies, Neoplasm | 1 | 2014 | 35 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2014 | 15 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2014 | 17 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2015 | 187 | 0.030 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2014 | 14 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2017 | 389 | 0.030 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2014 | 46 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2015 | 249 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2016 | 285 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 320 | 0.030 |
Why?
|
| Pregnancy | 1 | 2007 | 7191 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2016 | 233 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2017 | 437 | 0.030 |
Why?
|
| CpG Islands | 1 | 2014 | 165 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 521 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2015 | 372 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 268 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2015 | 423 | 0.030 |
Why?
|
| Research Personnel | 1 | 2016 | 186 | 0.030 |
Why?
|
| Models, Biological | 1 | 2021 | 1822 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2015 | 598 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2020 | 701 | 0.020 |
Why?
|
| Mass Screening | 1 | 2022 | 1348 | 0.020 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2013 | 24 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 32 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2013 | 91 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2014 | 481 | 0.020 |
Why?
|
| Ribosomal Protein S6 | 1 | 2012 | 18 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 466 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2013 | 64 | 0.020 |
Why?
|
| Gene-Environment Interaction | 1 | 2014 | 180 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2015 | 397 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2013 | 219 | 0.020 |
Why?
|
| Mortality | 1 | 2015 | 376 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2012 | 67 | 0.020 |
Why?
|
| Morbidity | 1 | 2013 | 323 | 0.020 |
Why?
|
| Washington | 1 | 2013 | 147 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2013 | 325 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2014 | 340 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2015 | 485 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2013 | 322 | 0.020 |
Why?
|
| Protein Binding | 1 | 2018 | 2276 | 0.020 |
Why?
|
| Amino Acids | 1 | 2015 | 522 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 1496 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 286 | 0.020 |
Why?
|
| Adolescent | 3 | 2019 | 22453 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 854 | 0.020 |
Why?
|
| Anemia | 1 | 2012 | 188 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2015 | 1095 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2014 | 682 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2012 | 573 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2022 | 17101 | 0.020 |
Why?
|
| Prevalence | 1 | 2016 | 2836 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2010 | 222 | 0.020 |
Why?
|
| Machine Learning | 1 | 2015 | 587 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2014 | 683 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 1327 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2010 | 306 | 0.020 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2009 | 99 | 0.020 |
Why?
|
| Age Distribution | 1 | 2009 | 403 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 2114 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 1407 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 1077 | 0.020 |
Why?
|
| Age of Onset | 1 | 2009 | 551 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2014 | 2050 | 0.020 |
Why?
|
| Registries | 1 | 2015 | 2385 | 0.020 |
Why?
|
| Social Support | 1 | 2010 | 652 | 0.010 |
Why?
|
| Survivors | 1 | 2009 | 520 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 780 | 0.010 |
Why?
|
| Anxiety | 1 | 2010 | 1110 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 2947 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 6053 | 0.010 |
Why?
|
| Child | 1 | 2015 | 22657 | 0.010 |
Why?
|